FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesDirect-to-Patient Survey Results Summary
Topics: Health Care, Innovation, Supply Chain
Report
Free
Brexit & the future landscape for clinical trial supplies in the UK and Europe
Topics: Pharma Industry, Regulatory, Supply Chain
Position Paper
Free
PATIENT Receptivity to Direct-to-Patient Shipment in Clinical Trials - a GCSG sponsored study
Topic: Direct-to-Patient
White Paper
Members
